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Abstract
Background: To examine labour market participation and long-term sick leave following a diagnosis with myasthenia
gravis (MG) compared with the general Danish population and for specific subgroups of MG patients.
Methods: A nationwide matched cohort study from 1997 to 2011 using data from population-based medical and
social registries. The study includes 330 MG patients aged 18 to 65 years old identified from hospital diagnoses and
dispensed prescriptions, and twenty references from the Danish population matching each MG patient on age, gender,
and profession. Main outcome measures are labour market participation (yes/no) and long-term sick leave ≥9 weeks
(yes/no) with follow-up at 1- and 2 years after the time of MG diagnosis or match. Based on complete person-level
information on all public transfer payments in Denmark, persons having no labour market participation are defined as
individuals receiving social benefits for severely reduced workability, flexijob, and disability pension.
Results: MG is consistently associated with higher odds of having no labour market participation and long-term sick
leave compared with the general Danish population (no labour market participation & ≥9 weeks sick leave at 2-year
follow-up, adjusted OR (95% CI): 5.76 (4.13 to 8.04) & 8.60 (6.60 to 11.23)). Among MG patients, females and patients
treated with both acetylcholinesterase inhibitors and immunosuppression have higher odds of lost labour market
participation and long-term sick leave.
Conclusions: This study suggests that MG patients have almost 6 times higher odds of no labour market participation
and almost 9 times higher odds of long-term sick leave 2 years after diagnosis compared with the general Danish
population. In particular female MG patients and patients treated with both acetylcholinesterase and immunosuppression
have high odds of a negative labour market outcome. Future research should focus on predictors in workplace and
labour market policy of labour market participation among MG patients.
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Background
Myasthenia gravis (MG) is a chronic, autoimmune, neuro-
muscular disease with a prevalence of approximately 20 per
100,000 [1]. The annual incidence is reported as being 1.7–
10.4 patients per 1,000,000 residents [1]. Incidence rates
have increased in recent years, mostly due to improvement
in diagnostics. Advances in medical therapy have continu-
ously increased the life expectancy of MG patients without
definitively curing the disease [1–4]. MG affects mainly
females (about 70%) and two age-related incidence peaks
can be detected among females and men: among females
between 20 and 40 years and among men between 60 and
80 years of age [1, 5, 6]. Females constitute up to 70% of all
MG patients below 40 years of age [6].
The majority of scientific literature on MG focuses on
epidemiology, immunopathogenesis, clinical presentations,
diagnosis, and treatment of MG, including emerging thera-
peutic strategies [1, 7–10]. As life expectancy for MG
patients has increased due to advances in treatment
and a general increase in life expectancy, research in
the past decade has increasingly focused on the conse-
quences of MG in terms of quality of life. These studies in-
dicate a reduction in health-related quality of life (HRQoL),
compared to normative values or control groups, and
this negative effect is more prominent in physical do-
mains [11–14].
However, only little attention has been devoted to the
social consequences of MG. Studies have shown that
only 30% of a MG population was employed [15], and
that MG is associated with increased risk of long periods
of unemployment [16]. It has also been shown, that
employment is associated with improved quality of life
among MG patients [15]. Therefore, the aim of this
study was to analyze the labour market trajectories in
terms of labour market participation and long-term sick
leave following a MG diagnosis compared with the general
population, and for specific groups of MG patients.
Methods
This nationwide matched cohort study was conducted in
Denmark from 1997 to 2011 based on prospectively
collected data from population-based medical and social
registries. Since 1968, all Danish residents have been
assigned a unique 10-digit personal identification number,
which is used in all databases and allows for explicit
person-level linkage between databases [17]. The study
was approved by the Danish Data Protection Agency
(journal no. 2012-41-0867).
Data sources
The Danish National Patient Register holds records of
all patients admitted to Danish somatic hospitals since
1977 and outpatient activities, emergency room contacts,
and activities in psychiatric wards since 1995. The Registry
contains administrative and clinical data for both inpatient-
and outpatient hospital contacts, including discharge diag-
noses coded according to the International Classification of
Diseases (ICD), version 8 until 1994 and subsequently
version 10 [18].
The Danish National Prescription Registry includes data
on all prescriptions dispensed at outpatient pharmacies
since 1994. The registry contains information on the drug
user, the dispensing, the prescriber and the pharmacy, in-
cluding information on the date of each dispensing and
the global Anatomical Therapeutic Chemical classification
(ATC) code identifying each dispensed drug in a five-level
classification system [19].
The Danish Register for Evaluation of Marginalisation
(DREAM) holds person-level information on all public
transfer payments since 1991 registered on a weekly basis.
The register contains more than 100 specific codes for
transfer income, including detailed coding on e.g. un-
employment, leave of absence, retirement, sick leave,
social assistance (transfer income administered by the
municipal social service department), grants from the
State Education Fond, and flexijob (job created for per-
sons with limited work capacity applying normal wage
and a public benefit transferred to the employer) [20].
Other nationwide population-based Danish registries
give access to person-level sociodemographic characteristics
on e.g. profession, marital status, and vital status [21, 22].
MG patients
Patients with MG were included if 1) aged 18–65 years
old and 2) registered in The Danish National Patient
Register with MG (ICD-10 DG70.0) including both in-
patient and outpatient hospital contacts, and 3) having ≥2
dispensed prescriptions with acetylcholinesterase inhibi-
tors (AChEI) (ATC-code N07AA02) [23]. A total of 399
MG patients fulfilled these criteria during 1 January 1997
to 31 December 2011. A nationwide clinical database for
MG neurorehabilitation further identified 6 MG patients
during 1997–2011 of whom 4 patients had hospital
contact for MG but did not have ≥2 dispensed AChEI
prescriptions, and 2 MG patients only had ≥2 dispensed
AChEI prescriptions. Among these 405 MG patients, we
excluded 75 MG patients who had no labour market par-
ticipation, were retired, or were unavailable for follow-up
at baseline assessed 1 year before diagnosis due to a
varying time span from symptom onset until being diag-
nosed, leaving a total of 330 MG patients.
Study population
The reference group consisted of randomly selected
subjects without MG from the Danish population.
Only references having no hospital contact in the year
of MG diagnosis were included. Twenty references
were selected to match each of the 330 MG patients at
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the time of diagnosis on integer values of age, gender,
and approximately 100 categories of profession prior
to diagnosis/match. The registry establish profession
ultimo November each year for all Danish citizens.
Outcome variables
Follow-up on labour market participation and long-term
sick leave ended after 1 and 2 years from the date of
diagnoses for MG patients and date of matching for refer-
ences. Labour market participation was based on weekly
coding of social transfer payments in DREAM, and dichot-
omized into “yes” and “no”. The category “yes” includes
people who were self-supporting or receiving social benefits
for which a minimum of workability is an eligibility criteria,
such as sick leave, occupational rehabilitation, unemploy-
ment, education, and maternity leave. The category “no” in-
cludes people receiving social benefits granted for severe
reduced workability, flexijob or unemployed as such, and
disability pension. Research indicates that sick leave length,
and in particular more than 8 weeks of absence, is a pre-
dictor of future reduced workability [24], and weeks of sick
leave from the time of diagnosis/match were therefore
assessed in categories of 0–8 weeks and 9–52 (1-year
follow-up) and 0–8 weeks and 9–104 (2-years follow-up),
respectively.
Co-variables
Baseline data at the time of diagnosis were included on
age, gender, marital status, profession, weeks of sick leave
1 year prior to diagnosis/match, and time period. Pharma-
cological treatment with both acetylcholinesterase inhibi-
tors (ATC-code N07AA02) and immunosuppression was
also included as a covariate since initial treatment with
acetylcholinesterase inhibitors is generally supplemented
with immunosuppression when MG symptoms are not ad-
equately controlled, and MG treatability may likely associ-
ate with prognosis [1]. Treatment with immunosuppression
includes the following ATC-codes: S01BA04 (prednisol-
one), L04AX01 (azathioprine), L04AA06 (mycophenolic
acid), L04AD01 (ciclosporin), L04AD02 (tacrolimus),
L01AA01 (cyclophosphamide), or L01BA01 (methotrexate).
Statistical analysis
Age was included as an integer variable, but was catego-
rized into early onset (18–39 years) versus late onset (40+
years) [5, 6] when analyzing the association between age
and labour market outcome among MG patients. Baseline
data on profession was classified in 4 groups (employer/dir-
ector, employee, not employed, pension/early retirement).
Although MG patients on retirement 1 year before
diagnosis were excluded from analyses, some patients
changed labour market status before November when
profession was assessed, and as a result the baseline data
on profession includes a category for persons on pension/
early retirement. Due to a non-normal distribution, weeks
of prior sick leave were categorized into 0 weeks (no sick
leave), 1–8 weeks (short-term sick leave) and 9+ weeks
(long-term sick leave). Time period was categorized into
1/1 1997-1/6 2008 and 2/6 2008-1/1 2012 reflecting that
Danish employers received no reimbursement of sickness
benefit from the state in the first 14/15 days of sick leave
during the period 1/1 1997 to 1/6 2008 and in the first
21 days during the period 2/6 2008 to 1/1 2012.
Baseline characteristics of MG patients and matched
references were compared with means, standard devia-
tions and percentages. The associations between MG
and labour market participation as well as sick leave
were assessed 1 and 2 years after diagnosis/match using
logistic regression adjusting for the co-variables and data
categories shown in Table 1 to obtain odds ratios (OR)
and 95% confidence intervals (CI). Similar analyses were
performed exclusively in MG patients to evaluate the
association between specific patient characteristics and
labour market participation as well as sick leave. Less
Table 1 Baseline characteristics: a national cohort of patients






Age, m (sd) 42.7 (13.0) 42.7 (13.0)
Male, n (%) 130 (39.4) 2600 (39.4)
Profession, n (%)
Employer/director 31 (9.4) 620 (9.4)
Employee 240 (72.7) 4800 (72.7)
Not employed 57 (17.3) 1140 (17.3)
Pension/early retirement 2 (0.6) 40 (0.6)
Marital status, n (%)
Married/registered
partnership
197 (59.7) 3712 (56.2)
Not married/registered
partnership
130 (39.4) 2885 (43.7)
Missing 3 (0.9) 3 (<0.1)
Pharmacological treatment, n (%)
AChEI 158 (47.9) –
AChEI+ 172 (52.1) –
Prior sick leave (1 year), n (%)
0 weeks 190 (57.6) 5851 (88.7)
1–8 weeks 80 (24.2) 477 (7.2)
9–52 weeks 60 (18.2) 272 (4.1)
Time period
1/1 1997–1/6 2008 249 (75.5) 4980 (75.5)
2/6 2008–31/12 2011 81 (24.6) 1620 (24.6)
Abbreviations: AChEI Acetylcholinesterase inhibitors, AChEI+ AChEI
and immunosuppression
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than 0.1% of MG patients and matched references had
missing data on marital status (Table 1), and these patients
were excluded from the adjusted analyses.
To evaluate the robustness of our findings, the analyses
were performed excluding patients who died during
follow-up. Furthermore, the analyses were repeated in-
cluding the 75 MG patients who were excluded from the
primary analyses because they had only minimal or no risk
of event at baseline or were unavailable for follow-up (and
their matched pairs). Finally, the analyses were performed
excluding the matched references who had only minimal
or no risk of event at baseline or were unavailable for
follow-up (and their matched pairs). All sensitivity ana-
lyses were performed with logistic regression adjusting for
the co-variables in Table 1 to obtain OR and 95% CI.
All analyses were performed in Stata 13 as two-tailed
analyses considering p < 0.05 statistically significant.
Results
A total of 2 MG patients (0.6%) and 4 matched refer-
ences (0.1%) died during 1-year follow-up, and 3 MG
patients (0.9%) and 21 matched references (0.3%) died
during 2-year follow-up. MG patients and the matched
references were compatible with regard to age, gender,
and profession with a mean age of 42.7 years, females
constituting 60.6% of both groups, and more than 80%
were in employment. Slightly more of the MG patients
were married or in registered partnership (60.2%) than
among the matched references (56.3%). Among the
MG patients, 47.9% received pharmacological treatment
with solely acetylcholinesterase inhibitors, whereas the
remaining 52.1% received further treatment with im-
munosuppression. MG patients more often had a
labour market history involving sickness absence 1 year
before diagnosis compared to the matched references
(Table 1).
Initial analysis of labour market participation and sick
leave after time of diagnosis showed that MG patients sub-
sequently experienced labour market trajectories with gen-
erally poorer labour market participation than the matched
references both at 1- and 2-year follow-up, and more often
suffered from long-term sick leave. In the first year after
diagnosis, 41.2% of the MG patients experienced 9 or more
weeks of sickness absence. The corresponding figure in the
reference group was 3.4%. This trend was also observed at
2-year follow-up, where 47% of MG patients had been sick-
listed for more than 9 weeks. The corresponding figure
among the matched references was 6.8% (Table 3).
Logistic regression analysis showed that MG patients had
significantly higher odds of having no labour market par-
ticipation. The odds were more than two-fold after 1 year,
and almost a factor 6 at the 2-year follow-up. The asso-
ciation between pharmacological treatment and labour
market participation was only significant after 2 years,
where those receiving both acetylcholinesterase inhibi-
tors and immunosuppression had an OR of 1.95 for no
labour market participation compared to those receiving
solely acetylcholinesterase inhibitors. There were no dif-
ferences in labour market participation according to age
among MG patients. Female MG patients had significantly
higher odds of lost labour market participation at 2 years,
compared to male MG patients (Table 2).
MG patients had profound excess odds of sickness
absence exceeding 9 weeks at both 1 and 2-year follow-
up compared with matched references. The OR for MG
patients at 1 and 2 years were 14.8 and 8.6 respectively
in the adjusted models. Among MG patients, age, gen-
der and pharmacological treatment were not associated
with sick leave at 1-year follow-up. At 2-year follow-up,
most adjusted models showed excess odds of sickness
absence among females, whereas age and pharmaco-
logical treatment were not significantly associated with
sick leave (Table 3).
The results in Tables 2 and 3 were largely confirmed
by analyses including only survivors. In the two analyses
either including MG-patients or excluding matched ref-
erences with minimal or no risk of event at baseline
(and their matched pairs), all point estimates suggested
that MG patients above 39 years have higher odds of
having no labour market participation than MG patients
younger than 40 years, although not all results reached
statistical significance.
Discussion
The study showed that MG patients more often had a
labour market history involving sickness absence than the
matched references, and generally experienced poorer
labour market participation and suffered from long-term
sick leave at 1- and 2 year follow-up, respectively. The ex-
cess odds of having no labour market participation among
MG patients were approximately 2- and 6-fold at 1- and
2-year follow-up. The ORs among MG patients for sick-
ness absence exceeding 9 weeks at the two follow-ups
were approximately 15 and 9, respectively. With regard to
gender, female MG patients had significantly higher odds
of experiencing long-term sickness absence and having no
labour market participation at 2 years after time of diag-
nosis, than male MG patients. The results were largely
confirmed by several sensitivity analyses.
Strengths and weaknesses of the study
A main strength of this study is the prospective study
design, the large nationwide cohort identified from both
inpatient and outpatient hospital contacts as well as
dispensed prescriptions, and the detailed and complete
data on labour market participation [20]. All data were
prospectively collected unaware of the study hypotheses,
minimizing the risk of selection and information bias.
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Furthermore, confounding was minimized by matching
and adjusting for potentially strong confounders, including
previous sickness absence [25], profession [26, 27], marital
status [27], and gender [26, 27]. Although residual con-
founding may exist, adjustment for these factors represents
a considerable strength of the study.
Because of the observational design, the results may be
affected by unaccounted confounding from e.g. work en-
vironment and health behaviour, modifying the observed
associations in an unknown direction [27, 28]. Co-morbid
diseases may also be a potential confounder [26, 29]. How-
ever, research shows that life expectancy in MG patients
do not differ significantly from the general population
which was also confirmed in our study where only minor
differences in mortality were seen between MG patients
and the general population [29]. This may indicate that
MG patients and non-MG patients were balanced with
respect to prognostic factors with heavy impact on
mortality, including a range of co-morbid diseases. The
observed minor differences in mortality may be a result of
matching where only individuals with no hospital contacts
in the year of MG diagnosis were selected which may
potentially introduce bias towards stronger associations
between MG and poor labour market participation. Fur-
thermore, misclassification in labour market outcomes
may exist due to a flexible Danish labour market enabling
different possible working scenarios for MG patients, e.g.
MG patients working part-time without transfer payment
instead of having transfer payments due to part-time sick
leave. The direction and magnitude of this potential bias is
unknown. However, the observed findings are despite
these fallacies substantiated by the pronounced strength of
associations, the plausible findings and consistency in
results compared with other research [30].
Comparison with other studies
Research from other countries supports our findings that
MG is associated with increased sickness absence and







Comparison groups No LMP, 1 year after diagnosis/match
MG vs. matched references 35 (10.6)/309 (4.7) 2.42 (1.67–3.49) 2.23 (1.46–3.38)
MG: age 40+ vs. 18–39 22 (11.2)/13 (9.7) 1.18 (0.57–2.43) 2.02 (0.84–4.86)
MG: male vs. female 10 (7.7)/25 (12.5) 0.58 (0.27–1.26) 0.67 (0.28–1.59)
MG: AChEI+ vs. AChEI 21 (12.2)/14 (8.9) 1.43 (0.70–2.92) 1.26 (0.57–2.78)
Comparison groups No LMP, 2 years after diagnosis/match
MG vs. matched references 75 (22.7)/327 (5.0) 5.64 (4.26–7.47) 5.76 (4.13–8.04)
MG: age 40+ vs. 18–39 44 (22.5)/31 (23.1) 0.96 (0.57–1.62) 1.21 (0.64–2.27)
MG: male vs. female 19 (14.6)/56 (28.0) 0.44 (0.25–0.78) 0.39 (0.20–0.74)
MG: AChEI+ vs. AChEI 49 (28.5)/26 (16.5) 2.02 (1.18–3.45) 1.95 (1.09–3.50)
Abbreviations: LMP labour market participation, MG myasthenia gravis, AChEI Acetylcholinesterase inhibitors, AChEI+ AChEI + immunosuppression. OR odds ratio, CI
confidence interval
aAdjusted for age, gender, profession, marital status, pharmacological treatment, sick leave 1 year before diagnosis/match, and time period







Comparison groups ≥9 weeks sick leave, 1 year after diagnosis/match
MG vs. matched references 136 (41.2)/225 (3.4) 19.86 (15.37–25.67) 14.80 (10.97–19.95)
MG: age 40+ vs. 18–39 84 (42.9)/52 (38.8) 1.18 (0.76–1.85) 1.25 (0.70–2.24)
MG: male vs. female 50 (38.5)/86 (43.0) 0.83 (0.53–1.30) 0.66 (0.38–1.15)
MG: AChEI+ vs. AChEI 76 (44.2)/60 (38.0) 1.29 (0.83–2.01) 1.17 (0.70–1.96)
Comparison groups ≥9 weeks sick leave, 2 years after diagnosis/match
MG vs. matched references 155 (47.0)/448 (6.8) 12.16 (9.60–15.41) 8.60 (6.60–11.23)
MG: age 40+ vs. 18–39 94 (48.0)/61 (45.5) 1.10 (0.71–1.71) 1.34 (0.76–2.36)
MG: male vs. female 53 (40.8)/102 (51.0) 0.66 (0.42–1.0) 0.50 (0.29–0.86)
MG: AChEI+ vs. AChEI 91 (52.9)/64 (40.5) 1.65 (1.07–2.55) 1.61 (0.98–2.64)
Abbreviations: MG myasthenia gravis, AChEI Acetylcholinesterase inhibitors, AChEI+ AChEI + immunosuppression, OR odds ratio, CI confidence interval
aAdjusted for age, gender, profession, marital status, pharmacological treatment, sick leave 1 year before diagnosis/match, and time period
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loss of labour market participation. An Australian study
showed that approximately 40% out of 165 MG patients
stopped working due to MG, and nearly 20% changed
occupation or reduced work hours (mean disease dur-
ation not published) [31]. During a 1-year period, about
one fifth of the patients were on sick leave of which 7%
were on long-term sick leave (≥9 weeks) [31]. A German
study including 1518 MG patients with mean disease
duration of 10.2 years found that only 25.5% of the
patients worked more than 15 h per week, and almost 70%
had no labour market participation [15]. An Italian study of
101 MG patients showed that 20% of the patients stopped
working prior to retirement age [32]. The studies are hardly
comparable with this study because of differences in study
design, outcome measures, and follow-up periods, but all
studies suggest that MG is negatively correlated with labour
market participation and sickness absence. We are unaware
of any studies assessing the causal mechanisms in the link
between MG and weak labour market participation. How-
ever, a study has shown that both a Dutch and Norwegian
MG population had reduced HRQol assessed by SF-36, pri-
marily caused by limitations in their physical health leading
to restrictions in participation in everyday life [33]. General-
ized fatigue in addition to muscle fatigue is a frequent
symptom and has reached a growing focus [34]. Further-
more, concomitant autoimmune diseases and side-effects
by treatment may also have a negative influence on labour
market participation [29, 30]. Our study suggests that MG
have a particularly high negative impact on sick leave
during the first year after diagnosis, and a high negative
impact on labour market participation during the second
year after diagnosis compared with the general Danish
population. This may indicate that a disproportion exists
between patient resources and the workplace- or labour
market requirements and adaptations which may in the
long term hinder MG patients from participating in the
workforce [30]. Future research should focus on pre-
dictors in workplace and labour market policy of
labour marked participation among MG patients in
order to optimize efforts to keep the MG patients in the
workforce.
MG is characterized by fluctuating symptoms but
studies suggest that MG symptoms and optimized treat-
ment have stabilized for up to 90% of the patients by
3 years after MG onset [35, 36]. However, the exact time
of disease onset is difficult to assess and the diagnostic
period most likely varies across countries, probably
depending on the clinical presentation of the patients,
including the AchR-serologic profile, and differences in
health care organization. Likewise differences exist in
labour market policies between countries with a high
impact on labour market participation. Although this
study includes a complete national population of MG
patients over 18 years, special attention must be given to
specific health care organization and labour market pol-
icies before generalizing the results to other countries
and settings.
Conclusions
The study shows that MG is associated with higher odds
of having no labour market participation and increased
long-term sick leave compared with the general Danish
population during the first 2 years after diagnosis. In
particular female patients and patients treated with both
acetylcholinesterase inhibitors and immunosuppression
have higher odds of lost labour market participation and
long-term sick leave than male patients and patients treated
with acetylcholinesterase inhibitors alone. Future research
should identify predictors in workplace and labour market
policy of labour marked participation among MG patients.
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